Pfizer Inc. PFE
Verdict: Strong sell. Fair value $25.63 against a price of $25.68 on 6 Jan 2026.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Competitive moat at risk of erosion. Intense competitive pressure could compress margins. GAAP Net Income swung dramatically from $31.37B in 2022 to just $2.12B in 2023 (a 93% decline),....
Main risks
- Severe Revenue & Profit Collapse: Revenue has fallen ~38% from its 2022 peak, with Net Income and FCF declining even more sharply, highlighting the significant post-COVID 'cliff' and uncertainty in the core business.
- Extremely Poor Returns on Capital: ROIC of 3.3% is likely below WACC, indicating value destruction. The estimated 3-year ROIIC is deeply negative (-222%), a severe red flag suggesting capital deployed over the last three years has been value-destructive.
- High Leverage Relative to Cash Flow: A Net Debt to EBITDA ratio of approximately 4.9x is elevated and poses a financial risk, especially in the context of declining earnings and profitability.
- GAAP Net Income swung dramatically from $31.37B in 2022 to just $2.12B in 2023 (a 93% decline),...
- Revenue fell over 41% from $101.17B in 2022 to $59.55B in 2023, driven by the sharp decline in...
- Intense competitive environment